Targeting cannabinoid signaling for peritoneal dialysis-induced oxidative stress and fibrosis

Table 1 Summary of cannabinoid signaling on modulation of diseases with increased oxidative stress

Disease	Species	Disease model	Ref.
Diabetes mellitus
Microvascular complications
Nephropathy	Mouse	In vivo	[49,50]
Retinopathy	Mouse, rat	In vivo	[43,44]
Neuropathy	Mouse, rat	In vivo	[45-47]
Macrovascular complications	Mouse, rat	In vivo	[40,41]
Cardiomyopathy
Diabetic cardiomyopathy	Mouse	In vivo	[57]
	Human cardiomyocyte	In vitro	[57]
Myocardial ischemia/reperfusion	Mouse	In vivo	[51,53,54]
Ageing-related cardiomyopathy	Mouse	In vivo	[55]
Doxorubicin-induced cardiomyopathy	Mouse	In vivo	[52,56]
	Human cardiomyocyte	In vitro	[56]
	Rat cardiomyocyte	In vitro	[52]
Cisplatin nephropathy	Mouse	In vivo	[68,69]
Liver injury/fibrosis
Ischemia/reperfusion hepatocyte injury	Mouse	In vivo	[59]
CCl4-induced hepatocyte injury	Mouse	In vivo	[59]
Alcoholic liver fibrosis	Mouse	In vivo	[62]
Fibrotic activation of hepatic stellate cells	Human, rat, mouse	In vitro	[58,60,63,64]
Biliary diseases
Cholangiopathies	Mouse	In vivo	[65]
	Mouse cholangiocyte	In vitro	[65]
Enteric diseases
Inflammatory bowel disease	Mouse	In vivo	[66]
Colitis	Mouse	In vivo	[67]
Autoimmune systemic sclerosis	Mouse	In vivo	[70]